Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy

医学 肥厚性心肌病 内科学 心脏病学 心室流出道梗阻 射血分数 安慰剂 心室流出道 酒精间隔消融 心力衰竭 梗阻性心肌病 病理 替代医学
作者
Martin S. Maron,Theodore P. Abraham,Caroline Coats,Iacopo Olivotto,Matthew M.Y. Lee,Michael Arad,Nuno Cardim,Changsheng Ma,Lubna Choudhury,Hans‐Dirk Düngen,Pablo García‐Pavía,Albert Hagège,Gregory D. Lewis,Michelle Michels,Artur Oręziak,Anjali Owens,Jacob Tfelt‐Hansen,Josef Veselka,Hugh Watkins,Stephen B. Heitner,Daniel Jacoby,Stuart Kupfer,Fady I. Malik,Lisa Meng,Amy Wohltman,Ahmad Masri
出处
期刊:Journal of Cardiac Failure [Elsevier BV]
卷期号:30: S3-S3
标识
DOI:10.1016/j.cardfail.2023.11.006
摘要

Background Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by myocardial hypercontractility with left ventricular outflow tract obstruction (LVOTO), reduced exercise capacity, and heart failure symptoms. Aficamten is a next-in-class cardiac myosin inhibitor with unique physicochemical properties that appear to safely and effectively reduce LVOTO and improve symptoms and cardiac biomarkers (REDWOOD-HCM; NCT04219826). SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction, Impact of Aficamten in HCM; NCT05186818) is the pivotal Phase 3 trial evaluating the safety and efficacy of aficamten in patients with symptomatic oHCM and objective evidence of reduced functional capacity. Herein we present the baseline characteristics of patients enrolled in SEQUOIA-HCM. Methods SEQUOIA-HCM is an international, multicenter, randomized, double-blind, placebo-controlled trial in patients with symptomatic (NYHA class II–III) oHCM (left ventricular ejection fraction [LVEF] ≥60%; left ventricular outflow tract gradient [LVOT-G] ≥30 mmHg at rest and ≥50 mmHg with Valsalva), and peak oxygen uptake (pVO2) ≤80% of age- and sex-predicted maximum. Patients were randomized (1:1) to either oral placebo or aficamten, with site-based echocardiographic guidance to achieve individualized daily doses of 5, 10, 15, or 20 mg. The primary efficacy outcome is change in pVO2 on exercise testing from baseline to Week 24. Results SEQUOIA-HCM has enrolled 282 patients. Available patient characteristics at baseline are shown in Table 1. The mean (SD) age was 59.1 (12.9) years, 40.8% were female, and 22% were non-white. Baseline New York Heart Association functional class was Class II for 203 patients (72%), Class III for 67 patients (23.8%), and Class IV for 1 patient (0.4%). Just over half of the patients (172; 61%) were treated with beta-blockers. The mean baseline pVO2 was 18.5 (SD 4.5) mL/kg/min or 57.2% of predicted maximum, and the mean Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 74.7 (SD 18.1). Geometric mean (Q1, Q3) high-sensitivity cardiac troponin I was 16.9 (7.7, 27.2) ng/L. At this time, LVEF, LVOT-G, and N-terminal pro–B-type natriuretic peptide remain blinded measures. Conclusion SEQUOIA-HCM has enrolled a diverse and representative oHCM population with baseline characteristics reflecting significant symptom burden. Results will provide guidance on the utility of aficamten, a next-in-class cardiac myosin inhibitor, in patients with symptomatic oHCM. Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by myocardial hypercontractility with left ventricular outflow tract obstruction (LVOTO), reduced exercise capacity, and heart failure symptoms. Aficamten is a next-in-class cardiac myosin inhibitor with unique physicochemical properties that appear to safely and effectively reduce LVOTO and improve symptoms and cardiac biomarkers (REDWOOD-HCM; NCT04219826). SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction, Impact of Aficamten in HCM; NCT05186818) is the pivotal Phase 3 trial evaluating the safety and efficacy of aficamten in patients with symptomatic oHCM and objective evidence of reduced functional capacity. Herein we present the baseline characteristics of patients enrolled in SEQUOIA-HCM. SEQUOIA-HCM is an international, multicenter, randomized, double-blind, placebo-controlled trial in patients with symptomatic (NYHA class II–III) oHCM (left ventricular ejection fraction [LVEF] ≥60%; left ventricular outflow tract gradient [LVOT-G] ≥30 mmHg at rest and ≥50 mmHg with Valsalva), and peak oxygen uptake (pVO2) ≤80% of age- and sex-predicted maximum. Patients were randomized (1:1) to either oral placebo or aficamten, with site-based echocardiographic guidance to achieve individualized daily doses of 5, 10, 15, or 20 mg. The primary efficacy outcome is change in pVO2 on exercise testing from baseline to Week 24. SEQUOIA-HCM has enrolled 282 patients. Available patient characteristics at baseline are shown in Table 1. The mean (SD) age was 59.1 (12.9) years, 40.8% were female, and 22% were non-white. Baseline New York Heart Association functional class was Class II for 203 patients (72%), Class III for 67 patients (23.8%), and Class IV for 1 patient (0.4%). Just over half of the patients (172; 61%) were treated with beta-blockers. The mean baseline pVO2 was 18.5 (SD 4.5) mL/kg/min or 57.2% of predicted maximum, and the mean Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 74.7 (SD 18.1). Geometric mean (Q1, Q3) high-sensitivity cardiac troponin I was 16.9 (7.7, 27.2) ng/L. At this time, LVEF, LVOT-G, and N-terminal pro–B-type natriuretic peptide remain blinded measures. SEQUOIA-HCM has enrolled a diverse and representative oHCM population with baseline characteristics reflecting significant symptom burden. Results will provide guidance on the utility of aficamten, a next-in-class cardiac myosin inhibitor, in patients with symptomatic oHCM.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
pcr163应助linhanwenzhou采纳,获得50
刚刚
刚刚
酷酷元风完成签到,获得积分10
1秒前
2秒前
天才幸运鱼完成签到,获得积分10
2秒前
3秒前
3秒前
粥游天下完成签到,获得积分10
4秒前
jcc完成签到,获得积分10
4秒前
哈哈哈哈完成签到,获得积分10
4秒前
lighthouse完成签到,获得积分10
5秒前
平凡中的限量版完成签到,获得积分10
5秒前
大伟完成签到,获得积分10
5秒前
long关注了科研通微信公众号
6秒前
懵懂的毛豆完成签到,获得积分10
6秒前
zzcherished发布了新的文献求助10
6秒前
zyq发布了新的文献求助10
6秒前
我是老大应助哦哦哦采纳,获得10
7秒前
YHY完成签到,获得积分10
7秒前
7秒前
天天呼的海角完成签到,获得积分10
10秒前
量子星尘发布了新的文献求助10
13秒前
13秒前
13秒前
jiangcai完成签到,获得积分10
14秒前
Cherry完成签到,获得积分10
16秒前
正能量的可可可完成签到,获得积分10
16秒前
tuo zhang发布了新的文献求助10
19秒前
草莓养乐多完成签到 ,获得积分10
19秒前
糊涂完成签到,获得积分10
19秒前
哦哦哦发布了新的文献求助10
19秒前
in完成签到 ,获得积分10
20秒前
pilot完成签到,获得积分10
22秒前
劣根完成签到,获得积分10
23秒前
Liang发布了新的文献求助20
23秒前
25秒前
26秒前
曾小莹完成签到,获得积分10
26秒前
苏信怜完成签到,获得积分10
27秒前
30秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029